Spondyloarthritis & psoriatic arthritis
Response to netakimab in radiographic axial spondyloarthritis patients with different baseline C-reactive protein, sacroiliitis evaluated by magnetic resonance imaging (MRI) and peripheral joint involvement status: a post-hoc analysis of the ASTERA study
Authors' conclusion
Subcutaneous netakimab is effective in patients with r-axSpA irrespective of baseline CRP and inflammation on SIJ MRI. The benefit in patients with high CRP (>20 mg/L) was more pronounced.
Study context
- Population
- Adults with active radiographic axial spondyloarthritis (r-axSpA) treated with netakimab 120 mg SC in the ASTERA phase 3 study, with available baseline C-reactive protein (CRP) and sacroiliac joint (SIJ) MRInetakimab-treated, of 228 in ASTERA
- Participants
- 114 adults
- Comparison
- Netakimab response by baseline CRP (<5 vs ≥5 mg/L), MRI sacroiliitis (SPARCC <2 vs ≥2) and peripheral arthritis status
- Primary endpoint
- ASAS-recommended activity, spinal mobility and function endpoints for r-axSpA
- Follow-up
- Week 16
Methodological detailsdouble-blinded, multicentre, placebo-controlled, phase 3
- Double-blinded
- Multicentre
- Placebo-controlled
- Phase 3
Primary result
As reported in the abstract
Response to netakimab by subgroup
- Improvement in all outcomes similar for MRI-SI- and MRI-SI+, except change in ASspi-MRI-a significantly greater in MRI-SI+
- Netakimab effective regardless of baseline CRP and PA
- CRP ≥5 mg/L: more pronounced decline in r-axSpA activity, with a trend towards the most prominent improvement in ASDAS-CRP and BASDAI for CRP >20 mg/L
- Post-hoc analysis
Original publication
Response to netakimab in radiographic axial spondyloarthritis patients with different baseline C-reactive protein, sacroiliitis evaluated by MRI and peripheral joint involvement status: a post-hoc analysis of the ASTERA study. Clin Exp Rheumatol. Published 8 February 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →